MedTrace Logo

Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)

NCT02996214 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 536

Last updated 2020-02-13

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy and the safety of paclitaxel liposome and cisplatin compared with gemcitabine and cisplatin as first-line therapy in advanced squamous non-small-cell lung cancer .

Conditions

  • Squamous Non-small-cell Lung Cancer

Interventions

DRUG

Paclitaxel Liposome

Paclitaxel liposome injection 175 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.

DRUG

Gemcitabine

Gemcitabine 1000 mg/m\^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles.

DRUG

Cisplatin

Cisplatin 75 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.

Sponsors & Collaborators

  • Nanjing Luye Sike Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • caicun zhou, doctor · Shanghai Pulmonary Hospital, Shanghai, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-12-31
Completion
2020-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02996214 on ClinicalTrials.gov